Boey can show results in hours and fade in weeks: Why AbbVie is betting shorter can be better
AbbVie wins European approval for Boey, a rapid-onset neurotoxin lasting two to three weeks, opening a new test of aesthetics demand.
Pharma & Biotech
Pharma & Biotech
AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared
AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.